Maravai Lifesciences Holdings (MRVI) Income from Continuing Operations (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Income from Continuing Operations of 6377000.0 for Q1 2026, up 87.93% year-over-year from 3393204.21 in Q1 2025, and up 89.88% quarter-over-quarter from 63015000.0 in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 6377000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 87.93% year-over-year to 6377000.0; the TTM figure through Mar 2026 stood at 184286000.0 (up 36.41% YoY), while the FY2025 annual figure was 230762000.0, up 11.12% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 6377000.0, up from 63015000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 156721000.0 in Q2 2022, with the low at 172455000.0 in Q3 2024.
- The 5-year median for Income from Continuing Operations is 18420000.0 (2024), against an average of 8498411.76.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations surged 94.61% in 2022, then sank 1582.49% in 2024.
- Maravai Lifesciences Holdings' Income from Continuing Operations stood at 87429000.0 in 2022, then plunged by 225.8% to 109982000.0 in 2023, then jumped by 58.11% to 46067000.0 in 2024, then sank by 36.79% to 63015000.0 in 2025, then jumped by 89.88% to 6377000.0 in 2026.
- Business Quant data shows MRVI's Income from Continuing Operations at 6377000.0 in Q1 2026, 63015000.0 in Q4 2025, and 45057000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | -21.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.63 Mn |
| Mar 31, 2026 | -6.38 Mn |
| Dec 31, 2025 | -63.02 Mn |
| Sep 30, 2025 | -45.06 Mn |
| Jun 30, 2025 | -69.84 Mn |
| Mar 31, 2025 | -52.85 Mn |
| Dec 31, 2024 | -46.07 Mn |
| Sep 30, 2024 | -172.46 Mn |
| Jun 30, 2024 | -18.42 Mn |
| Mar 31, 2024 | -22.68 Mn |
| Dec 31, 2023 | -109.98 Mn |
| Sep 30, 2023 | -15.10 Mn |
| Jun 30, 2023 | -11.94 Mn |
| Mar 31, 2023 | -1.35 Mn |
| Dec 31, 2022 | 87.43 Mn |
| Sep 30, 2022 | 99.65 Mn |
| Jun 30, 2022 | 156.72 Mn |
| Mar 31, 2022 | 146.86 Mn |
| Dec 31, 2021 | 127.11 Mn |
| Sep 30, 2021 | 132.18 Mn |